Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir

Journal of Medicinal Chemistry

Volumn 51, Issue 20, 2008, Pages 6599-6603

  Kovalevsky, Andrey Y ^a,c   Ghosh, Arun K ^b   Weber, Irene T ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; DARUNAVIR; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CALCULATION; COMPETITIVE INHIBITION; DRUG BINDING SITE; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME KINETICS; ENZYME STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; MEASUREMENT; MOLECULAR INTERACTION; MOLECULAR MODEL; MUTANT; NONHUMAN; PROTEINASE INHIBITION; WILD TYPE;

BINDING SITES; CARBAMATES; HIV PROTEASE INHIBITORS; HIV-1; KINETICS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; SULFONAMIDES;

EID: 54549105456     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800283k     Document Type: Article

References (30)

1. De Clercq, E. New Approaches toward Anti-HIV Chemotherapy. J. Med. Chem. 2005, 48, 1-17.
2. Wlodawer, A.; Vondrasek, J. Inhibitors of HIV-1 Protease: A Major Success of Structure-Assisted Drug Design. Annu. Rev. Biophys. Biomol. Struct. 1998, 27, 249-284.
3. Ghosh, A. K.; Chapsla; B.D.; Weber, I. T.; Mitsuya, H. Design of protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc. Chem. Res. 2008, 41, 78-86.
4. Weber, I. T.; Kovalevsky, A. Y.; Harrison, R. W. Structures of HIV Protease Guide Inhibitor Design to Overcome Drug Resistance. In Frontiers in Drug Design & Discovery; Caldwell, G. W.; Atta-ur-Rahman, M. R.; Player, M. I., Eds.; Bentham Science Publishers: Oak Park, IL, 2007, Vol. 3, pp 45-62.
5. Katlama, C.; Esposito, R.; Gatell, J. M.; Goffard, J. C.; Grinsztejn, B.; Pozniak, A.; Rockstroh, J.; Stoehr, A.; Vetter, N.; Yeni, P.; Parys, W.; Vangeneugden, T. Efficacy and safety of TMC114/ritonavir in treatment- experienced HIV patients: 24-week results of POWER 1. AIDS 2007, 21, 395-402.
6. Miller, M.; Schneider, J.; Sathyanarayana, B. K.; Toth, M.; Marshall, G. R.; Clawson, L.; Selk, L.; Kent, S. B. H.; Wlodawer, A. Structure of Complex of Synthetic HIV-1 Protease with a Substrate-Based Inhibitor at 2.3 Å Resolution. Science 1989, 246, 1149-1152.
7. 2+. Adv. Experim. Med. Biol. 1998, 436, 99-103.
8. Kovalevsky, A. Y.; Tie, Y.; Liu, F.; Boross, P. I.; Wang, Y.-W.; Leshchenko, S.; Ghosh, A. K.; Harrison, R. W.; Weber, I. T. Effectiveness of Nonpeptide Clinical Inhibitor TMC114 on HIV-1 Protease with Highly Drug Resistant Mutations D30N, I50V, and L90M. J. Med. Chem. 2006, 49, 1379-1387.
9. King, N. M.; Prabu-Jeyabalan, M.; Nalivaika, E. A.: Wigerinck, P.; de Béthune, M.-P.; Schiffer, C. A. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 2004, 78, 12012-12021.
10. Tie, Y.; Boross, P. I.; Wang, Y.-F.; Gaddis, L.; Hussain, A. K.; Leshchenko, S.; Ghosh, A. K.; Louis, J. M.; Harrison, R. W.; Weber, I. T. High Resolution Crystal Structures of HIV-1 Protease with a Potent Nonpeptide Inhibitor (UIC-94017) Active against Multidrug Resistant Clinical Strains. J. Mol. Biol. 2004, 338, 341-352.
11. Lam, P. Y. S.; Jadhav, P. K.; Eyennann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384.
12. Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme. J. Am. Chem. Soc. 1995, 117, 1181-1182.
13. Kaldor, S. W.; Kalish, V. J.; Davies, J. F., II.; Shetty, B. V.; Fritz, J. E.; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; Dressman, B. A.; Hatch, S. D.; Khalil, D. A.; Kosa, M. B.; Lubbehusen, P. P.; Muesing, M. A.; Patick, A. K.; Reich, S. H.; Su, K. S.; Tatlock, J. H. Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease. J. Med. Chem. 1997, 40, 3979-3985.
14. Sperka, T.; Pitlik, J.; Bagossi, P.; Tozser, J. Beta-lactam Compounds as Apparently Uncompetitive Inhibitors of HIV-1 Protease. Bioorg. Med. Chem. Lett. 2005, 15, 3086-3090.
15. Judd, D. A.; Nettles, J. H.; Nevis, N.; Snyder, J. P.; Liotta, D. C.; Tang, J.; Ermolieff, J.; Schinazi, R. F.; Hill, C. L. Polyoxometalate HIV-1 Protease Inhibitors. A New Mode of Protease Inhibition. J. Am. Chem. Soc. 2001, 123, 886-897.
16. De Voss, J. J.; Sui, Z.; DeCamp, D. L.; Salto, R.; Babe, L. M.; Craik, C. S.; Ortiz de Montellano, P. R. Haloperidol-based Irreversible Inhibitors of the HIV-1 and HIV-2 Proteases. J. Med. Chem. 1994, 37, 665-673.
17. Brynda, J.; Rezacova, P.; Fabry, M.; Horejsi, M.; Stouracova, R.; Soucek, M.; Hradilek, M.; Konvalinka, J.; Sedlacek, J. Inhibitor Binding at the Protein Interface in Crystals of a HIV-1 Protease Complex. Acta Crystallogr. 2004, D60, 1943-1948.
18. Kovalevsky, A. Y.; Liu, F.; Leshchenko, S.; Ghosh, A. K.; Loius, J. M.; Harrison, R. W.; Weber, I. T. Ultra-high resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114. J. Mol. Biol. 2006, 363, 161-173.
19. Koh, Y.; Nakata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamudram, T.; Kincaid, J. F.; Boross, P.; Wang, Y.-F.; Tie, Y.; Volarath, P.; Gaddis, L.; Harrison, R. W.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. Novel bis-Tetrahydrofuranylurethane-Containing Non-peptidic Protease Inhibitor (PI) TMC-114 (UIC-94017) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro. Antimicrob. Agents Chemother. 2003, 47, 3123-3129.
20. De Meyer, S.; Azijn, H.; Surleraux, D.; Jochmans, D.; Tahri, A.; Pauwels, R.; Wigerinck, P.; de Bethune, M.-P. TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates. Antimicrob. Agents Chemother. 2005, 49, 2314-2321.
21. Louis, J. M.; Clore, G. M.; Gronenborn, A. M. Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nat. Struct. Biol. 1999, 6, 868-875.
22. Mahalingam, B.; Louis, J. M.; Hung, J.; Harrison, R. W.; Weber, I. T. Structural implications of drug resistant mutants of HIV-1 protease: High resolution crystal structures of the mutant protease/substrate analog complexes. Prot. Struct. Funct. Genet. 2001, 43, 455-464.
23. Dierynck, I.; De Wit, M.; Gustin, E.; Keuleers, I.; Vandersmissen, J.; Hallenberger, S.; Hertogs, K. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007, 81, 13845-51.
24. Koh, Y.; Matsumi, S.; Das, D.; Amano, M.; Davis, D. A.; Li, J.; Leschenko, S.; Baldridge, A.; Shioda, T.; Yarchoan, R.; Ghosh, A. K.; Mitsuya, H. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J. Biol. Chem. 2007, 282, 28709-20.
25. Segel, I. H. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley & Sons, Inc. 1993,
26. Maibaum, J.; Rich, D. H. Inhibition of porcine pepsin by two substrate analogues containing statine: the effect of histidine at the P2 subsite on the inhibition of aspartic proteinases. J. Med. Chem. 1988, 31, 625-629.
27. Cornish-Bowden, A. Why is Uncompetitive Inhibition So Rare. FEBS 1986, 203, 3-6.
28. Porcelli, F.; Delfini, M.; Del Guidice, M. R. The Kinetic Inhibition of Acetylcholinesterase from Human Erythrocyte by Tacrine and Some Tacrine Derivatives. Bioorg. Chem. 1999, 27, 197-205.
29. Jin, P.; Bhattacharya, S. K. Anaerobic removal of pentachlorophenol in presence of zinc. J. Envir. Eng. 1996, 122, 590-598.
30. Lorey, S.; Stockel-Maschek, A.; Faust, J.; Brandt, W.; Stiebitz, B.; Gorrell, M. D.; Kahne, T.; Mrestani-Klaus, C.; Wrenger, S.; Reinhold, D.; Ansorge, S.; Neubert, K. Different Modes of Dipeptidyl Peptidase IV (CD26) Inhibition by Oligopeptides Derived from the N-terminus of HIV-1 Tat Indicate at Least Two Inhibitor Binding Sites. Eur. J. Biochem. 2003, 270, 2147-2156.